Please use this identifier to cite or link to this item:
https://repository.monashhealth.org/monashhealthjspui/handle/1/48476Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Kylie L. | - |
| dc.contributor.author | Kevin C. | - |
| dc.contributor.author | Matthew H. | - |
| dc.contributor.author | Nieroshan R. | - |
| dc.contributor.author | Paul M. | - |
| dc.contributor.author | Scott D. | - |
| dc.contributor.author | Weranja R. | - |
| dc.date.accessioned | 2022-08-23T05:38:49Z | - |
| dc.date.available | 2022-08-23T05:38:49Z | - |
| dc.date.copyright | 2022 | - |
| dc.date.issued | 2022-08-18 | en |
| dc.identifier.citation | Asia-Pacific Journal of Clinical Oncology. Conference: 2022 ANZUP Annual Scientific Meeting. Adelaide, SA Australia. 18(Supplement 1) (pp 77), 2022. Date of Publication: July 2022. | - |
| dc.identifier.uri | https://repository.monashhealth.org/monashhealthjspui/handle/1/48476 | - |
| dc.description.abstract | INTRODUCTION AND OBJECTIVES: Although randomised studies demonstrate a survival benefit with neoadjuvant chemotherapy (NAC) prior to cystectomy (RC) in muscle-invasive bladder cancer (MIBC), concerns remain about delay in surgical treatment and progression in non-responders. There is no Australian data on patterns of NAC use prior to cystectomy. Our aim was to evaluate the patterns of NAC and adjuvant chemotherapy (AC) use for MIBC in a single tertiary centre. METHOD(S): Patients who had a histologic diagnosis of >= pT2 urothelial carcinoma and subsequent RC at our centre between 2011 and 2021 were retrospectively identified. Patient, chemotherapy and tumour data were collected and analysed. RESULT(S): Of a total of 120 patients, 70 had a RC for pT2+ bladder cancer. Of these patients, six (8.6%) received NAC prior to RC, 20 (28.6%) received AC and two (2.9%) received adjuvant radiotherapy. 19 patients (27.1%) developed metastases and 20 (28.6%) died at a median followup of 20.8 (IQR 7.3- 53.9) months. Of the patients who received NAC, the median time from diagnosis to RC was 3.8 months (IQR 2.1 -4.6). Of these, four (66.7%) had downstaging to pT1 disease at RC, one (16.7%) developed metastases and two (33%) died on follow-up. The median time from cystectomy to AC was 1.6 months and Gemcitabine and Cisplatin were most frequently used (55%). 26 patients out of 46 (56.5%) who were eligible for AC did not receive chemotherapy with the most common reason being patients being unfit (10.9%) and patients declining treatment (10.9%). Of the 20 patients who received AC, five (25%) developed metastases and six (30%) died following AC. There was no difference in progression-free survival or overall survival between those who received NAC and AC. CONCLUSION(S): Majority of patients undergoing RC received AC compared to NAC, reflecting real-world practice. Further studies on the determinants of real-world selection for NAC are needed. | - |
| dc.publisher | Blackwell Publishing Ltd | - |
| dc.relation.ispartof | Asia-Pacific Journal of Clinical Oncology | - |
| dc.subject.mesh | adjuvant chemotherapy | - |
| dc.subject.mesh | adjuvant radiotherapy | - |
| dc.subject.mesh | bladder cancer | - |
| dc.subject.mesh | cancer adjuvant therapy | - |
| dc.subject.mesh | cancer patient | - |
| dc.subject.mesh | cancer surgery | - |
| dc.subject.mesh | cancer survival | - |
| dc.subject.mesh | cystectomy | - |
| dc.subject.mesh | histology | - |
| dc.subject.mesh | metastasis | - |
| dc.subject.mesh | muscle invasive bladder cancer | - |
| dc.subject.mesh | progression free survival | - |
| dc.subject.mesh | surgery | - |
| dc.subject.mesh | transitional cell carcinoma | - |
| dc.subject.mesh | cisplatin | - |
| dc.subject.mesh | gemcitabine | - |
| dc.title | Patterns of chemotherapy use for muscle-invasive bladder cancer at a single tertiary institution in Australia. | - |
| dc.type | Conference Abstract | - |
| dc.identifier.affiliation | Urology | - |
| dc.description.conferencename | 2022 ANZUP Annual Scientific Meeting | - |
| dc.description.conferencelocation | Adelaide, SA, Australia | - |
| dc.type.studyortrial | Observational study (cohort, case-control, cross sectional or survey) | - |
| dc.identifier.doi | http://monash.idm.oclc.org/login?url=https://dx.doi.org/10.1111/ajco.13827 | - |
| local.date.conferencestart | 2022-07-10 | - |
| dc.identifier.institution | (Kylie, Kevin, Matthew, Nieroshan, Paul, Scott, Weranja) Department of Urology, Monash Health, Australia | - |
| local.date.conferenceend | 2022-07-12 | - |
| dc.identifier.affiliationmh | (Kylie, Kevin, Matthew, Nieroshan, Paul, Scott, Weranja) Department of Urology, Monash Health, Australia | - |
| item.fulltext | No Fulltext | - |
| item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
| item.openairetype | Conference Abstract | - |
| item.grantfulltext | none | - |
| item.cerifentitytype | Publications | - |
| Appears in Collections: | Conference Abstracts | |
Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.
